P

Inventor

STONE EVERETT

US33 patents
⚠️ This page may combine multiple inventors who share the name “STONE EVERETT”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

UNIV TEXAS

22 patents
US9808486B2Nov 7, 2017

Administration of kynurenine depleting enzymes for tumor therapy

UNIV TEXAS17 citations92
US9481877B2Nov 1, 2016

Engineered primate L-methioninase for therapeutic purposes

UNIV TEXAS14 citations92
US10772913B2Sep 15, 2020

Administration of kynurenine depleting enzymes for tumor therapy

UNIV TEXAS5 citations84
US10363311B2Jul 30, 2019

Engineered primate cystine/cysteine degrading enzymes as antineogenic agents

UNIV TEXAS4 citations84
US10233438B2Mar 19, 2019

Engineered primate L-methioninase for therapeutic purposes

UNIV TEXAS6 citations83
US9975959B2May 22, 2018

Administration of kynurenine depleting enzymes for tumor therapy

UNIV TEXAS8 citations83
US9624484B2Apr 18, 2017

Engineered primate L-methioninase for therapeutic purposes

UNIV TEXAS11 citations83
US11534463B2Dec 27, 2022

Nucleic acids encoding kynurenine depleting enzymes

UNIV TEXAS1 citations73
US10716856B2Jul 21, 2020

Engineered primate cystine/cysteine degrading enzymes as antineogenic agents

UNIV TEXAS2 citations73
US11168142B2Nov 9, 2021

Administration of kynurenine depleting enzymes for tumor therapy

UNIV TEXAS5 citations72
US10724026B2Jul 28, 2020

Engineered primate L-methioninase for therapeutic purposes

UNIV TEXAS2 citations72
US11648272B2May 16, 2023

Human kynureninase enzymes and uses thereof

UNIV TEXAS2 citations70
US11118167B2Sep 14, 2021

Enzyme-mediated depletion of adenosine and/or methylthioadenosine

UNIV TEXAS3 citations64
US12036269B2Jul 16, 2024

Human-enzyme mediated depletion of homocysteine for treating patients with hyperhomocysteinemia and homocystinuria

UNIV TEXAS0 citations62
US11591579B2Feb 28, 2023

Human methylthioadenosine/adenosine depleting enzyme variants for cancer therapy

UNIV TEXAS0 citations62
US11426464B2Aug 30, 2022

Engineered primate cystine/cysteine degrading enzymes as antineogenic agents

UNIV TEXAS0 citations62
US11396647B2Jul 26, 2022

Human methylthioadenosine/adenosine depleting enzyme variants for cancer therapy

UNIV TEXAS0 citations62
US11033612B2Jun 15, 2021

Human-enzyme mediated depletion of homocysteine for treating patients with hyperhomocysteinemia and homocystinuria

UNIV TEXAS0 citations62
US11542486B2Jan 3, 2023

Human kynureninase enzyme variants having improved pharmacological properties

UNIV TEXAS1 citations61
US12163168B2Dec 10, 2024

Engineered primate cystine/cysteine degrading enzymes for therapeutic uses

UNIV TEXAS0 citations59
US12144828B2Nov 19, 2024

Human Kynureninase enzymes and uses thereof

UNIV TEXAS0 citations59
US10865403B2Dec 15, 2020

Engineered primate cystine/cysteine degrading enzymes for therapeutic uses

UNIV TEXAS1 citations56

AEMASE INC

4 patents

GEORGIOU GEORGE

3 patents

AERASE INC

3 patents

ANTIDOTE THERAPEUTICS INC

1 patent